Clinical Report: Acute Mania Induced by Lurasidone Treatment in a Patient with Bipolar I Disorder
Overview
Expand to include details about the patient's previous treatments and their effects.
Background
Lurasidone is a second-generation antipsychotic approved for treating bipolar depression, but it can induce manic episodes in susceptible patients. Understanding the risks associated with lurasidone is critical for clinicians, especially in patients with a history of bipolar disorder. Vigilance during treatment initiation is essential to prevent adverse outcomes.
Data Highlights
No numerical data or trial data presented in the article.
Key Findings
A 43-year-old male with bipolar I disorder developed acute mania after lurasidone titration.
Initial symptoms included severe depression, insomnia, and suicidal ideation.
After one week of lurasidone treatment, the patient exhibited increased energy and decreased sleep.
By the second week, he experienced a full manic episode with irritability and significantly reduced sleep.
Immediate discontinuation of lurasidone and optimization of sodium valproate led to stabilization of the patient's condition.
Clinical Implications
Clinicians should closely monitor patients with bipolar I disorder for manic symptoms when initiating or adjusting lurasidone therapy. Early identification and intervention can significantly reduce morbidity associated with manic episodes.
Conclusion
This case highlights the potential for lurasidone to induce mania in patients with bipolar I disorder, emphasizing the need for careful monitoring during treatment initiation.
